Entering text into the input field will update the search result below

Ocular Therapeutix: Catalysts Stacking

May 06, 2021 10:35 AM ETOcular Therapeutix, Inc. (OCUL)KOD, NVS, REGN14 Comments
BioSci Capital Partners profile picture
BioSci Capital Partners
16.05K Followers

Summary

  • Ocular Therapeutix is a multi-bagger stock with substantial upsides. Despite over two-fold gains, I believe it can appreciate higher due to pending catalysts.
  • Dextenza is poised to gain the label expansion for the treatment of allergic conjunctivitis.
  • In the longer horizon, Ocular's Eylea reformulation is likely to become a mega blockbuster.
  • I do much more than just articles at Integrated BioSci Investing: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
Eye Exam
Photo by Geber86/E+ via Getty Images

This is the usual route by which a management not content with one isolated spurt of growth sees that growth occurs in a series of more or less continuous spurts. - The Father of Growth Investing (Philip Fisher, i.e., Warren Buffet's mentor).

Thanks for reading! To read the full article, CLICK HERE. To get the latest articles, please hit the orange “Follow” button on top.

Be sure to check out our private investment research community, Integrated BioSci Investing.

Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.

Very professional, extremely knowledgeable and very honest … I would highly recommend this service and his stock picks have been very profitable.

Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.

Click here for a FREE TRIAL.

This article was written by

BioSci Capital Partners profile picture
16.05K Followers
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.  Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains. Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook. In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstance are individualized.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (14)

j
Single digits coming tomorrow. You may be able to buy below $9 shortly.
S
@jrnpanther the price hasn’t gone below $9 as was predicted.
M
Does anyone have any thoughts about Regeneron ending their relationship with Ocular? I'm long OCUL but this news makes me nervous. Does it mean Regeneron had lost faith in OCUL?
t
@Marcosjf
Can you post a link to this news?
t
@Marcosjf
Found it myself…can’t call this good news in any form.

www.businesswire.com/...™-Announces-Termination-of-the-Collaboration-with-Regeneron-to-Develop-a-Sustained-Release-Formulation-of-Aflibercept-for-the-Treatment-of-Wet-AMD-and-other-Serious-Retinal-Diseases
j
Had it for a few months before the pandemic wasn't moving sales were slow but might be the time to buy and hold
Why did I choose the airlines profile picture
Great Call !

I have serious eye conditions. This along with Regenerex Bio assure me that my condition will be OK .

Again TY!
BioSci Capital Partners profile picture
@Why did I choose the airlines Thanks for commenting on my article. I'm glad that you like the research!
Why did I choose the airlines profile picture
@BioSci Capital Partners I like it . I don’t always agree with it but your calls are real real detailed.
s
@BioSci Capital Partners what not since regeneron is gone.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.